CellCentric secures investment from American Cancer Society's impact venture capital fund to advance inobrodib, its ground-breaking p300/CBP targeted therapy
/PRNewswire/ -- CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces...
Source: prnewswire.com